Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells

被引:262
作者
Özvegy, C
Litman, T
Szakács, G
Nagy, Z
Bates, S
Váradi, A
Sarkadi, B
机构
[1] Hungarian Acad Sci, Natl Inst Haematol & Immunol, Membrane Res Grp, H-1113 Budapest, Hungary
[2] Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary
[3] Herlev Univ Hosp, Lab Oncol, DK-2730 Herlev, Denmark
[4] SOLVO Biotechnol Co, Res Grp, H-6722 Szeged, Hungary
[5] NCI, Med Branch, NIH, Bethesda, MD 20892 USA
基金
匈牙利科学研究基金会;
关键词
multidrug resistance; ABC half-transporter; ABCG2; MXR; BCRP; Sf9; cells; drug-stimulated ATPase activity;
D O I
10.1006/bbrc.2001.5130
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ABCG2 (also called MXR (3), BCRP (4), or ABCP (5)) is a recently-identified ABC half-transporter, which causes multidrug resistance in cancer. Here we report that the expression of the ABCG2 protein in Sf9 insect cells resulted in a high-capacity, vanadate-sensitive ATPase activity in isolated membrane preparations. ABCG2 was expressed underglycosylated, and its ATPase activity was stimulated by daunorubicin, doxorubicin, mitoxantrone, prazosin and rhodamine 123, compounds known to be transported by this protein. ABCG2-ATPase was inhibited by low concentrations of Na-orthovanadate, N-ethylmaleimide and cyclosporin A Verapamil had no effect, while Fumitremorgin C, reversing ABCG2-dependent cancer drug resistance, strongly inhibited this ATPase activity. The functional expression of ABCG2 in this heterologous system indicates that no additional partner protein is required for the activity of this multidrug transporter, probably working as a homodimer, We suggest that the Sf9 cell membrane ATPase system is an efficient tool for examining the interactions of ABCG2 with pharmacological agents. (C) 2001 Academic Press.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 33 条
[21]  
NAKAGAWA M, 1992, CANCER RES, V52, P6175
[22]   Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone [J].
Nielsen, D ;
Eriksen, J ;
Maare, C ;
Litman, T ;
Kjærsgaard, E ;
Plesner, T ;
Friche, E ;
Skovsgaard, T .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (03) :363-370
[23]  
Rabindran SK, 1998, CANCER RES, V58, P5850
[24]  
RAO US, 1994, MOL PHARMACOL, V45, P773
[25]   Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitroxantrone-selected cell lines [J].
Ross, DD ;
Yang, WD ;
Abruzzo, LV ;
Dalton, WS ;
Schneider, E ;
Lage, H ;
Dietel, M ;
Greenberger, L ;
Cole, SPC ;
Doyle, LA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (05) :429-433
[26]   Expression of breast cancer resistance protein in blast cells from patients with acute leukemia [J].
Ross, DD ;
Karp, JE ;
Chen, TT ;
Doyle, LA .
BLOOD, 2000, 96 (01) :365-368
[27]  
SARKADI B, 1992, J BIOL CHEM, V267, P4854
[28]   DRUG-STIMULATED ATPASE ACTIVITY OF THE HUMAN P-GLYCOPROTEIN [J].
SCARBOROUGH, GA .
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 1995, 27 (01) :37-41
[29]  
SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474
[30]   PRESENTATION OF VIRAL-ANTIGEN BY MHC CLASS-I MOLECULES IS DEPENDENT ON A PUTATIVE PEPTIDE TRANSPORTER HETERODIMER [J].
SPIES, T ;
CERUNDOLO, V ;
COLONNA, M ;
CRESSWELL, P ;
TOWNSEND, A ;
DEMARS, R .
NATURE, 1992, 355 (6361) :644-646